Home Health & Wellness The IL-2 Human: A Cornerstone in Immunotherapy

The IL-2 Human: A Cornerstone in Immunotherapy

Reading Time: 3 minutes

Interleukin-2 (IL-2) is a critical cytokine in the human immune system, primarily known for its role in the activation and proliferation of T-cells. Discovered in the mid-1970s, IL-2 has since become a focal point in immunotherapy, especially in the treatment of various cancers and chronic infections. Its therapeutic potential lies in its ability to modulate the immune system, enhancing the body’s natural defence mechanisms against malignancies.

Biological function of IL-2

Activated CD4+ T cells produce IL-2, a glycoprotein. Initiating a chain of intracellular signals that help T-cells grow, differentiate, and stay alive, it binds to the IL-2 receptor (IL-2R) on the surface of immune cells. This cytokine also plays a pivotal role in the development of regulatory T-cells (Tregs), which are essential for maintaining immune tolerance and preventing autoimmune diseases.

The IL-2/IL-2R interaction is crucial for the immune system’s ability to mount an effective response to pathogens and malignancies. It promotes the expansion of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, both of which are key players in identifying and destroying infected or cancerous cells.

IL-2 in vancer immunotherapy

The therapeutic potential of IL-2 was first recognized in the context of cancer treatment. In the 1980s, high-dose IL-2 (HDIL-2) therapy was approved for metastatic renal cell carcinoma (RCC) and later for metastatic melanoma. The mechanism behind IL-2’s efficacy in cancer therapy involves the activation and expansion of T-cells and NK cells, which enhance the immune system’s ability to target and eliminate cancer cells.

High-dose IL-2 therapy can induce durable remissions in a subset of patients with metastatic cancers. Severe toxicities, such as vascular leak syndrome, which can result in life-threatening complications, limit its use. These side effects arise due to IL-2’s ability to increase vascular permeability, causing fluids and proteins to leak from blood vessels into surrounding tissues.

Advancements in IL-2 therapy

Given the limitations of HDIL-2 therapy, researchers have developed strategies to improve its safety and efficacy. One approach involves the use of lower doses of IL-2 in combination with other immunotherapies, such as checkpoint inhibitors. This combination has shown promise in enhancing anti-tumor responses while minimising toxicity.

Another significant advancement is the development of engineered IL-2 variants. These changed cytokines are meant to activate effector T-cells and NK cells more than Tregs, which can weaken the immune system’s ability to fight tumours. Such modifications aim to enhance the therapeutic window of IL-2, providing potent anti-cancer effects with fewer side effects.

IL-2 in autoimmune diseases and chronic infections

Beyond oncology, IL-2 has potential therapeutic applications in autoimmune diseases and chronic infections. Low-dose IL-2 therapy has been explored as a treatment for autoimmune disorders such as systemic lupus erythematosus (SLE) and type 1 diabetes. In these conditions, IL-2 helps restore immune tolerance by promoting the expansion of Tregs, which suppress aberrant immune responses.

In the context of chronic infections, IL-2 can boost the immune system’s ability to combat persistent pathogens. For example, in HIV infection, IL-2 has been used to increase CD4+ T-cell counts, helping to improve immune function in patients with advanced disease.

Future perspectives

The future of IL-2 therapy lies in refining its use to maximise benefits while minimizing risks. Ongoing research aims to develop more selective IL-2 variants and to identify biomarkers that predict patient response to therapy. Personalised approaches, tailoring IL-2 treatment to individual patients based on their unique immune profiles, hold promise for improving outcomes.

Moreover, combining IL-2 with other immunotherapeutic agents, such as cancer vaccines and adoptive cell transfer, represents a promising avenue for enhancing its efficacy. As our understanding of the immune system deepens, IL-2 is likely to remain a cornerstone of immunotherapy, offering hope for patients with a variety of challenging diseases.

IL-2 is a powerful cytokine with significant therapeutic potential. Its ability to modulate the immune system makes it a valuable tool in the treatment of cancer, autoimmune diseases, and chronic infections. Continued advancements in IL-2 therapy hold the promise of improved efficacy and safety, paving the way for better clinical outcomes.




Adam Mulligan, a psychology graduate from the University of Hertfordshire, has a keen interest in the fields of mental health, wellness, and lifestyle.

© Copyright 2014–2034 Psychreg Ltd